Nevertheless, such combinations only provided limited clinical benefits, demonstrating overall survival (OS) ranging from 12 to 17 months.5–7 Notably, immunochemotherapy mainly benefits a subset of PD-L1-positive ESCC patients,5,8 potentially because of the immune evasion caused by vascular abnormalities.9 Here, CD274 is linked to esophageal squamous cell carcinoma.